stockrow
Friday 6 November 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
- EPS
- +21.3%
- Free cash flow
- +11.9%
Quarter to June 2026, against a year earlier
2.44
0.08
+3.39%
Follow KLRS
Alert me
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | 5.69 | 2.70 | — | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | — | — | — | — | — | — |
P/Operating CF |
— | (6.00) | (6.00) | — | — | — | — | — | — |
P/B ratio |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
— | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Sales |
— | 0.00 | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
— | 0.83 | 0.83 | — | — | — | — | — | — |
EV/FCF |
— | 0.83 | 0.83 | — | — | — | — | — | — |
Quick Ratio |
— | 6.76 | 13.88 | 29.02 | 6.56 | 9.61 | 6.49 | 0.07 | 12.15 |
Current Ratio |
— | 6.77 | 13.98 | 29.39 | 6.69 | 9.99 | 6.61 | 0.11 | 12.23 |
Net Debt/EBITDA |
— | 6.94 | 4.61 | 4.96 | 1.42 | 1.33 | 0.92 | (0.35) | 2.54 |
Debt/Assets |
0.00% | 0.00% | 2.20% | 0.87% | 2.30% | 2.59% | 0.00% | 317.12% | 0.00% |
Debt/Equity |
— | 0.00 | (0.06) | 0.01 | 0.03 | 0.03 | 0.00 | (0.20) | 0.00 |
Asset Turnover |
— | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.24) | 0.85 | 0.87 | 0.62 | 0.84 | 0.65 | 0.30 | 0.88 |
Capex/Depreciation |
— | — | (17.84) | (3.22) | (0.14) | 0.00 | 0.00 | — | 0.52 |
Interest Coverage |
— | (128.43) | (12.93) | (53.62) | (129.14) | (91.26) | — | (19.15) | (31.98) |
| — | 19.86% | 58.06% | (46.28%) | (59.47%) | (75.02%) | (102.85%) | (281.37%) | 488.01% | |
| — | (64.43%) | (28.94%) | (27.35%) | (52.31%) | (59.86%) | (81.40%) | (70.24%) | (67.93%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (37.80%) | (20.11%) | (19.95%) | (79.23%) | (76.81%) | (119.56%) | 313.02% | (39.82%) |
Average Days of Receivables |
— | 97.12 | 659.21 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
— | 149.78% | 9,847.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 267.05% | 6,435.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 1,751.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | 1.61 | 1.61 | — | — | — | — | — | — |
Graham Number |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
— | (1.69%) | (1.69%) | — | — | — | — | — | — |
Free Cash Flow Yield |
— | (62.70%) | (62.70%) | — | — | — | — | — | — |
Revenue per Share |
— | 0.02 | 2.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.03 | (360.55) | (51.98) | (38.93) | (42.60) | (27.51) | (15.47) | (2.51) |
Capex per Share |
— | 0.00 | (6.06) | (0.20) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) |
Free Cash Flow per Share |
— | 0.03 | (366.62) | (52.18) | (38.94) | (42.60) | (27.51) | (15.47) | (2.53) |
Cash per Share |
— | 0.38 | 2,255.40 | 304.55 | 90.85 | 70.11 | 40.66 | 1.23 | 7.73 |
Shareholders Equity per Share |
— | 0.33 | (921.34) | 301.76 | 82.48 | 67.33 | 32.22 | (72.32) | 5.16 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.33 | (921.34) | 301.76 | 82.48 | 67.33 | 32.22 | (72.32) | 5.16 |
Free Cash Flow |
— | 1.94 | (20.49) | (61.05) | (106.34) | (142.05) | (124.45) | (20.67) | (38.57) |
Working Capital |
— | 21.58 | 118.21 | 349.02 | 215.50 | 218.71 | 159.27 | (22.10) | 109.10 |
Capital Expenditures |
— | — | (0.34) | (0.23) | (0.03) | — | — | — | (0.20) |
Net Current Asset Value |
— | 21.58 | (63.61) | 343.56 | 192.02 | 190.49 | 142.62 | (100.17) | 75.89 |
EV/EBIT |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
— | 0.00 | 2.05 | 0.00 | 0.00 | — | — | — | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | — | 0.05 | 0.09 | 0.12 | 0.78 | 0.00 | — | 0.00 |
Cash ROIC |
— | 4.17% | (26.40%) | (8.57%) | (22.16%) | (30.52%) | (37.74%) | 27.40% | (19.60%) |
Accounts Receivable Turnover |
— | 2.63 | 0.55 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.43 | 0.30 | 0.37 | 0.25 | 0.10 | 0.18 | — | — |
Average Payables |
— | 0.39 | 0.39 | 0.80 | 4.66 | 5.68 | 4.88 | 4.16 | 1.42 |
Average Assets |
— | 12.66 | 82.37 | 255.12 | 328.71 | 281.84 | 233.94 | 98.48 | 63.95 |
Average Common Equity |
— | (41.06) | (41.06) | 150.78 | 289.17 | 224.89 | 185.15 | 24.58 | (8.90) |
Columns are period end dates · fundamentals updated 25 Oct 2026